Silver Book Fact

Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient. 

Ubel P, Berry S, Nadler E, Bell C, et al. In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival. Health Aff. 2012; 31(4): 709-717. http://content.healthaffairs.org/content/31/4/709.abstract

Reference

Title
In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival
Publication
Health Aff
Publisher
Project HOPE
Publication Date
2012
Authors
Ubel P, Berry S, Nadler E, Bell C, et al
Volume & Issue
Volume 31, Issue 4
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • The 1-year survival rate for lung cancer has increased from 37% in 1975 to 42% in 1999-2001, largely because of improvements to surgical techniques and with combined therapies.  
  • The 5-year survival rate for localized breast cancer, is 98%–an 18% increase since the 1950s.  
  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in development is designed to induce a powerful immune response to melanoma.  
  • A mammogram can detect breast cancer 1-3 years before a woman can feel a lump. Mammography screening for women 50 and older can reduce breast cancer mortality by 30%.  
  • A one percent reduction in lung, colorectal, breast, leukemia, pancreatic, and brain cancer mortality would reduce productivity costs by $814 million per year.